(1) The board may seek and accept money from any public or private entity for the purposes of implementing and maintaining the program. The board shall transmit any money it receives to the state treasurer, who shall credit the money to the prescription drug monitoring fund, which fund is hereby created. The money in the fund is subject to annual appropriation by the general assembly for the sole purpose of implementing and maintaining the program. The money in the fund must not be transferred to or revert to the general fund at the end of any fiscal year.
After implementing the program, the board shall seek gifts, grants, and donations onan annual basis for the purpose of maintaining the program. The board shall report annually to the health and human services committee of the senate and the health and insurance committee of the house of representatives, or any successor committees, regarding the gifts, grants, and donations requested, of whom they were requested, and the amounts received.
If, based upon the appropriations for the direct and indirect costs of the program,there is insufficient money to maintain the program, the division may collect an annual fee of no more than seventeen dollars and fifty cents for the fiscal years 2011-12 and 2012-13, twenty dollars for the fiscal years 2013-14 and 2014-15, and twenty-five dollars for each fiscal year thereafter, from an individual who holds a license from the division that authorizes him or her to prescribe a controlled substance, as defined in section 18-18-102 (5). The division shall set the fee pursuant to section 12-20-105 and shall collect the fee in conjunction with the license renewal fees collected pursuant to section 12-20-105. Money collected pursuant to this subsection (3) is credited to the prescription drug monitoring fund created in subsection (1) of this section.
Notwithstanding subsection (1) of this section, on July 1, 2020, the state treasurershall transfer two hundred sixty-seven thousand five hundred twenty-one dollars from the prescription drug monitoring fund created in subsection (1) of this section to the general fund.
Source: L. 2019: Entire title R&RE with relocations, (HB 19-1172), ch. 136, p. 1499, § 1, effective October 1. L. 2020: (4) added, (HB 20-1406), ch. 178, p. 811, § 7, effective June 29.
Editor's note: This section is similar to former § 12-42.5-405 as it existed prior to 2019.